๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A Southwest Oncology Group phase II trial of recombinant tumor necrosis factor in metastatic breast cancer

โœ Scribed by G. Thomas Budd; Stephanie Green; Laurence H. Baker; Evan P. Hersh; James K. Weick; C. Kent Osborne

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
175 KB
Volume
68
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Methotrexate, vinblastine, doxorubicin,
Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the hoosier oncology group
โœ Bruce J. Roth; George W. Sledge Jr; Stephen D. Williams; Steven C. Meyer; Rafat ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 490 KB ๐Ÿ‘ 2 views

Forty-six eligible patients with metastatic breast cancer (MBC) were treated with a combination of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) as first-line chemotherapy. Of 44 patients evaluable for response, 28 (64%) had an objective response, including seven (16%) who had a comp

A phase II trial of estramustine and eto
A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)
โœ Kenneth J. Pienta; Emily I. Fisher; Mario A. Eisenberger; Glenn M. Mills; J. Wen ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 73 KB ๐Ÿ‘ 2 views

BACKGROUND. The combination of oral estramustine and oral etoposide has generated response rates of 40ยฑ50% in patients with hormone refractory prostate cancer in single institution trials. This study tested this regimen in a multi-institutional setting. METHODS. Fifty-ยฎve patients were accrued over